Simulations Plus Extends Key Research Collaborations with U.S. FDA and NIEHS

Simulations Plus, Inc., a Nasdaq-listed company recognized for its expertise in model-informed and AI-accelerated drug development, has announced the extension of two significant research collaborations. These partnerships involve the U.S. Food and Drug Administration (FDA) and the National Institute of Environmental Health Sciences (NIEHS), both pivotal agencies in advancing public health and regulatory science. The extensions underscore the ongoing commitment of Simulations Plus to contribute cutting-edge computational modeling and simulation tools that enhance drug development and safety evaluation processes.

The collaboration with the FDA focuses on refining predictive models that support regulatory decision-making. By integrating advanced AI techniques with pharmacokinetic and pharmacodynamic modeling, Simulations Plus aids the FDA in improving the accuracy and efficiency of drug approval workflows. This partnership aligns with the FDA's broader initiative to incorporate innovative technologies that streamline drug evaluation and ensure patient safety. The extended research aims to further validate and expand the application of these models in various therapeutic areas.

Simultaneously, the extended collaboration with NIEHS centers on environmental health risk assessment. Simulations Plus contributes its modeling expertise to better understand the toxicological impacts of environmental chemicals. This work is crucial for developing predictive frameworks that assess human exposure risks and inform regulatory standards. By leveraging AI and mechanistic modeling, the partnership seeks to enhance the scientific foundation for environmental health policies and interventions.

These research collaborations highlight the increasing role of computational modeling and artificial intelligence in biopharma innovation and public health. Simulations Plus's involvement with leading federal agencies demonstrates the value of integrating technology-driven approaches into regulatory science. The extensions not only reinforce the company's position as a leader in the field but also signal a growing acceptance of model-informed drug development and risk assessment methodologies within regulatory environments.

Looking ahead, these partnerships are expected to accelerate the development of safer and more effective therapeutics, while also improving environmental health protections. The ongoing research will likely contribute to the evolution of regulatory frameworks that are more adaptive and data-driven. For stakeholders in the pharmaceutical and environmental health sectors, these collaborations represent a promising advancement in leveraging AI and modeling to address complex scientific challenges.

In summary, Simulations Plus's extended collaborations with the FDA and NIEHS mark a significant milestone in the integration of AI and modeling technologies into regulatory science. These efforts support enhanced drug development processes and environmental health risk assessments, ultimately benefiting public health outcomes.